3 Nonetheless, these drugs are still used by women of childbearing age, and even pregnant women, by self-medication or irrational prescriptions.
A different strategy, such as continuous longitudinal follow-up, is needed to collect reliable data on pregnant women. The health and demographic surveillance system (HDSS) platform of the INDEPTH Network is one such strategy that longitudinally documents millions of person-years and vital statistics relating to individuals in specific communities. 4 The HDSS can be used for pharmacovigilance for the general population, but specifi cally for pregnant women and other susceptible groups. For example, a study in Tanzania used an HDSS platform to monitor the safety of drugs during pregnancy.
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More recently, INDEPTH introduced CHESS, 6 a new generation of population surveillance operations that integrates across population and health facility data systems and links demographic, epidemiological, mortality, morbidity, clinical, laboratory, household, environmental, health systems, and other contextual data, with a unique electronic individual identification system throughout. CHESS will make pharmacovigilance more eff ective.
With more than 2 million people under longitudinal evaluation in African countries, this population could generate a suffi cient sample size of pregnant women for pharmacoepidemiological studies through all trimesters. Data collection staff are well trained in collecting data from sensitive vital events (eg, death, abortion, and medication, drug or vaccine adverse events). With CHESS, a form of enhanced HDSS, we could identify the main classes of medications used by pregnant women, prospectively determine the incidence and risk factors of suspected adverse events among pregnant women, identify and evaluate adverse eff ects that are likely to affect compliance and treatment outcomes, and, finally, demonstrate the feasibility of using the HDSS as a sustainable platform to assess the use and safety of medications to facilitate decision making in Africa.
